MARKET

PGEN

PGEN

Precigen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.410
+0.070
+5.22%
After Hours: 1.400 -0.01 -0.71% 16:11 07/01 EDT
OPEN
1.350
PREV CLOSE
1.340
HIGH
1.410
LOW
1.310
VOLUME
606.64K
TURNOVER
0
52 WEEK HIGH
6.63
52 WEEK LOW
1.120
MARKET CAP
292.85M
P/E (TTM)
-2.9835
1D
5D
1M
3M
1Y
5Y
Precigen to Participate in the Stifel 2022 Virtual Cell Therapy Summit
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in...
PR Newswire · 5d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 06/07 21:33
Precigen's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q1, Precigen's (NASDAQ:PGEN) reported sales totaled $32.02 million. Despite a 23.1% increase in earnings, the company posted a loss of $19.25 million.
Benzinga · 06/07 14:04
Precigen to Participate in the 2022 H.C. Wainwright Global Investment Conference
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in...
PR Newswire · 05/17 20:05
Need To Know: Analysts Are Much More Bullish On Precigen, Inc. (NASDAQ:PGEN) Revenues
Shareholders in Precigen, Inc. ( NASDAQ:PGEN ) may be thrilled to learn that the analysts have just delivered a major...
Simply Wall St. · 05/14 12:15
Earnings Update: Precigen, Inc. (NASDAQ:PGEN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Precigen, Inc. ( NASDAQ:PGEN ) defied analyst predictions to release its first-quarter results, which were ahead of...
Simply Wall St. · 05/11 10:29
Precigen GAAP EPS of -$0.10 beats by $0.03, revenue of $32M beats by $8.73M
Precigen press release (NASDAQ:PGEN): Q1 GAAP EPS of -$0.10 beats by $0.03. Revenue of $32M (+30.6% Y/Y) beats by $8.73M.
Seekingalpha · 05/09 21:14
-- Earnings Flash (PGEN) PRECIGEN Reports Q1 Revenue $32M, vs. Street Est of $23.3M
MT Newswires · 05/09 16:40
More
No Data
Learn about the latest financial forecast of PGEN. Analyze the recent business situations of Precigen Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
60.00%Buy
20.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PGEN stock price target is 12.20 with a high estimate of 17.00 and a low estimate of 6.00.
High17.00
Average12.20
Low6.00
Current 1.410
EPS
Actual
Estimate
-0.12-0.09-0.06-0.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 262
Institutional Holdings: 147.19M
% Owned: 70.87%
Shares Outstanding: 207.69M
TypeInstitutionsShares
Increased
51
10.23M
New
23
2.82M
Decreased
47
9.83M
Sold Out
20
671.71K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.68%
Pharmaceuticals & Medical Research
+0.97%
Key Executives
Chairman/Executive Director
Randal Kirk
President/Chief Executive Officer/Director
Helen Sabzevari
Chief Financial Officer
Harry Thomasian
Senior Vice President
Jeffrey Perez
Secretary
Donald Lehr
Lead Director/Independent Director
Robert Shapiro
Independent Director
Cesar Alvarez
Independent Director
Steven Frank
Independent Director
Vinita Gupta
Independent Director
Fred Hassan
Independent Director
Jeffrey Kindler
Independent Director
Dean Mitchell
Independent Director
James Turley
No Data
No Data
About PGEN
Precigen, Inc. (Precigen) is a synthetic biology company that focuses on its discovery and clinical-stage activities to advance gene and cellular therapies to target immuno-oncology, autoimmune disorders, and infectious diseases. Its therapeutic platforms, including UltraCAR-T, AdenoVerse immunotherapy, and ActoBiotics, are designed to precisely control the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells to treat underlying disease conditions. The Company’s lead clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. The Company also completed a Phase I study of INXN-4001, a non-viral triple-effector plasmid DNA, which is built on its UltraVector platform. It also has a robust pipeline of preclinical programs.

Webull offers kinds of Precigen Inc stock information, including NASDAQ:PGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PGEN stock methods without spending real money on the virtual paper trading platform.